Clinical Research

CNO is involved in clinical research within a wide array of neurological diseases. We believe in contributing to the development of new therapies and adding to the collective understanding of neurosciences and medicine.

Help Us Make Wheelchairs Obsolete

Clinical Research

Contributing to the development of new therapies. From intravenous treatments, to neuro-physiotherapy and Transcranial Magnetic Stimulation, our breadth of services allows us to not only provide better tailored solutions, but also to buttress our various expertise with clinical trials and unique research studies.

Areas of Research

Accessing cutting edge therapies.

Why clinical research?

At CNO, research and clinical practice go hand in hand.

We continuously participate in a number of clinical trials aiming to create better treatments for a variety of diseases: Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective.

Cutting-edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and to help advance the treatments themselves. When it comes to neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of doctors, nurses and patients.

Research complements our therapeutic approach.

Francois Jacques, Neurologist, Founder.

Current MS Trials

Phase 1 Research

Developing new treatments.

When new therapies are developed, they need to be tested by healthy individuals. We are establishing phase 1 research capabilities and are looking for people interested in participating in this important phase of clinical research. If you or someone you know is interested in participating in phase 1 research protocols please get in touch.

Research is at the Core of Our Practice

We participate in a number of clinical trials aiming to create advancements for the treatment of Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective. Cutting edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and, most importantly, to help advance the treatments themselves. When it comes to Neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of Doctors, Nurses and, most of all, patients.

Neurogym and Clinical Research

Until recently, there were few, if any, evidence based neurological treatments beyond that of the pharmacological variety. This is changing. Thanks to our NeuroGym, we now offer neuro-physiotherapy and custom designed training equipment to complement pharmacological approaches. The notion that specific physical exercises can help slow disease progression and speed up recovery, though often intuitively applied in other fields, is nonetheless novel to neurology. This gives us the opportunity to conduct cutting-edge evidence based research concerning the efficacy of combined treatment options. Best of all, it also gives patients the opportunity to take charge of their recovery.
Click here to find out more about NeuroGym.

In accordance with our mandate to provide the most comprehensive neurological care possible, we were the first to introduce Transcranial Magnetic Stimulation (“Mag-Stim“) to the Gatineau region. Mag-Stim’s efficacy in treating neurological issues is now well documented, and its use is no longer uncommon in the Ottawa-Gatineau region’s psychiatric centers.
Click here to find out more about Magnetic Stimulation.

That being said, we continue to be at the forefront of this treatment’s evolution; consistently developing new and better protocols thanks to our Neuro-Navigation, which allows us to actively and accurately plot the areas of the brain we stimulate with greater precision. Like every other neurological tool at Clinique Neuro-Outaouais, this allows us to not only research better treatments but also to provide a new level of customized care.

The Future

In the short term, it is our ability to combine treatments that provide the most avenue for increased efficacy; a complement to ongoing clinical research which promises gradual long term improvement. At Clinique Neuro-Outaouais, we’re excited to have had evidence based success in improving patient care. We invite you to read our blog, and to contact us in order to learn more about our ongoing research trials and the range of our services.

Why clinical research?

At CNO, research and clinical practice go hand in hand.

We continuously participate in a number of clinical trials aiming to create better treatments for a variety of diseases: Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective.

Cutting-edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and to help advance the treatments themselves. When it comes to neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of doctors, nurses and patients.

Research complements our therapeutic approach.

Francois Jacques, Neurologist, Founder.

Multiple Sclerosis

In the past few decades the MS field has witnessed a rapid expansion of new therapies. CNO has been involved for the past 25 years in the development of most of the new therapies for MS. CNO continues to contribute to the field and remains at the forefront of MS clinical research.

Myasthenia Gravis

The past decade has seen transformative developments in the treatment landscape of Myasthenia Gravis. New treatments with innovative mechanisms including B cell depletion, complement inhibitions, and neonatal FC receptor blockade are now available and offer the prospect of long-term disease remission.

Parkinson's Disease

Parkinson’s Disease research has achieved tremendous strides in the past decades. Research has ranged from better understanding of the underlying disease mechanisms and how to improve symptomatic treatments to interventions that slow down or halt the disease progression.

Multifocal Motor Neuropathy

Multifocal Motor Neuropathy (MMN) is a rare autoimmune disease affecting peripheral motor nerves. It is manifested by slowly progressive painless asymmetrical weakness of hand and/or legs without any sensory loss.

Amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a rare neurodegenerative disease affecting both the central and peripheral nervous systems, with an estimated incidence of 1 to 3 cases per 100,000 people per year.

Alzheimer’s Disease

Alzheimer’s Disease is a progressive and eventually fatal brain disease, responsible for 60-80% of all dementia cases. The disease processes begin decades before the onset of symptoms, making early detection and intervention a priority.

Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) (CIDP) is an autoimmune disease affecting the peripheral nervous system.

Glioblastoma Multiforme

Glioblastoma Multiforme is the most aggressive and common form of primary malignant brain tumor.